Effect of the oestrogen receptor antagonist fulvestrant on the cirrhotic rat lung

It has been postulated that cirrhosis‐related lung vasodilatation and the subsequent hepatopulmonary syndrome are partly explained by an increased estradiol level through an enhanced endothelial formation of nitric oxide (NO). In this study, we assessed whether the oestrogen receptor antagonist fulv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Fundamental & clinical pharmacology 2015-06, Vol.29 (3), p.269-277
Hauptverfasser:	Oswald-Mammosser, Monique, Rashid, Sherzad, Boehm, Nelly, Agin, Arnaud, Geny, Bernard, Schini-Kerth, Valérie, Charloux, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	angiogenesis Animals Cell Adhesion Molecules - metabolism cirrhosis Disease Models, Animal Estradiol - analogs & derivatives Estradiol - blood Estradiol - pharmacology Estrogen Receptor Antagonists - pharmacology fulvestrant Heme Oxygenase (Decyclizing) - metabolism hepatopulmonary syndrome Hepatopulmonary Syndrome - blood Hepatopulmonary Syndrome - etiology Hepatopulmonary Syndrome - pathology Hepatopulmonary Syndrome - prevention & control Life Sciences Liver Cirrhosis, Biliary - blood Liver Cirrhosis, Biliary - complications Liver Cirrhosis, Biliary - drug therapy Lung - blood supply Lung - drug effects Lung - metabolism Lung - pathology Macrophages - drug effects Macrophages - metabolism Male Microfilament Proteins - metabolism nitric oxide Nitric Oxide Synthase Type II - metabolism Nitric Oxide Synthase Type III - metabolism Phosphoproteins - metabolism Phosphorylation Rats, Wistar Tyrosine - analogs & derivatives Tyrosine - metabolism Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!